Characterization of immune checkpoint inhibitor‐induced cardiotoxicity reveals interleukin‐17A as a driver of cardiac dysfunction after anti‐PD‐1 treatment

• Published in: British journal of pharmacology Vol. 180; no. 6; pp. 740 - 761
• Main Authors: Gergely, Tamás G., Kucsera, Dániel, Tóth, Viktória E., Kovács, Tamás, Sayour, Nabil V., Drobni, Zsófia D., Ruppert, Mihály, Petrovich, Balázs, Ágg, Bence, Onódi, Zsófia, Fekete, Nóra, Pállinger, Éva, Buzás, Edit I., Yousif, Laura I., Meijers, Wouter C., Radovits, Tamás, Merkely, Béla, Ferdinandy, Péter, Varga, Zoltán V.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.03.2023
• Subjects: Animals; cancer immunotherapy; Cardiac function; Cardiotoxicity; Cardiotoxicity - etiology; cardio‐oncology; CD4 antigen; Cytotoxicity; Echocardiography; Heart Diseases; heart failure; Immune checkpoint inhibitors; Immune Checkpoint Inhibitors - adverse effects; Immunohistochemistry; Immunotherapy; Inflammation; Inflammation - complications; Interleukin-17; Mice; Mice, Inbred C57BL; Molecular modelling; Monoclonal antibodies; Myocarditis; nivolumab; pembrolizumab; Stat3 protein; Targeted cancer therapy; Thymus; Thymus gland; Transcriptomics; Ventricle; heart failure; pembrolizumab; cardiotoxicity; cardio-oncology; nivolumab; cancer immunotherapy

Background and Purpose Immune checkpoint inhibitors (ICI), such as anti‐PD‐1 monoclonal antibodies, have revolutionized cancer therapy by enhancing the cytotoxic effects of T‐cells against tumours. However, enhanced T‐cell activity also may cause myocarditis and cardiotoxicity. Our understanding of...